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MEK inhibitor, U0126, attenuates cisplatin-induced renal in-
jury by decreasing inflammation and apoptosis.
Background. Although inflammation and apoptosis are
known to play important roles in cisplatin nephrotoxicity, the
exact intracellular signaling mechanisms are not well under-
stood. Recent reports that extracellular signal-regulated kinase
(ERK1/2) pathway mediates cisplatin-induced caspase activa-
tion and apoptosis in cultured renal tubular cells led us to in-
vestigate the effect of MAPK/ERK kinase (MEK) inhibitor,
an immediate upstream of ERK1/2 in cisplatin-induced acute
renal failure (ARF) in mice.
Methods. The effect of MEK/ERK1/2 inhibition on kidney
tumor necrosis factor-a (TNF-a( gene expression, inflamma-
tion, the activation of tissue caspases, and apoptosis were ex-
amined in addition to its effects on renal function and histology
in cisplatin-induced ARF in mice.
Results. Pretreatment of MEK inhibitor, U0126, decreased
ERK1/2 phosphorylation following cisplatin administration
with significant functional and histologic protection. This ben-
eficial effect was accompanied by decrease in TNF-a gene ex-
pression level and inflammation, as well as in caspase 3 activity
and apoptosis.
Conclusion. These data provide evidence that ERK1/2 path-
way functions as an upstream signal for TNF-a–mediated
inflammation and caspase 3–mediated apoptosis in cisplatin-
induced ARF in mice and suggest that ERK1/2 can be a novel
therapeutic target in cisplatin nephrotoxicity.
Cisplatin is one of the most effective chemotherapeutic
agents used in the treatment of a variety of human solid
tumors. However, dose-related nephrotoxicity frequently
limits the use of optimal dose of this drug [1, 2]. Pri-
mary targets of cisplatin in kidney are proximal straight
and distal convoluted tubules, where it accumulates and
promotes cellular damage, and multiple mechanisms, in-
cluding oxidative stress, DNA damage, apoptosis, and re-
cently inflammation have been implicated to contribute
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to the pathogenesis of cisplatin-induced renal injury
[3–12].
In particular, recent observations that tumor necrosis
factor-a (TNF-a) increased following cisplatin adminis-
tration and inhibition of its production markedly attenu-
ated renal damage indicate that TNF-a, an inflammatory
cytokine, plays an important role in cisplatin-induced re-
nal injury, but precise intracellular signaling mechanisms
leading to increased TNF-a production still remain un-
known [6].
Caspases are a family of cell death proteases involved
in the initiation and execution phase of apoptosis and
several in vitro studies have demonstrated that cisplatin
activated multiple caspases, including caspase 8, 9, and 3,
leading to apoptotic cell death in cultured renal tubular
cell [13]. However, detailed pattern of activation in vivo
nor intracellular signaling mechanisms of caspase activa-
tion by cisplatin have not been fully examined.
Proteins comprising the mitogen-activated protein ki-
nase (MAPK) family are important mediators of signal
transduction processes that serve to regulate diverse cel-
lular responses to extracellular stimuli. Of the three major
mammalian MAPK superfamily, the extracelluar signal-
regulated kinases (ERK) pathway has been known to
play a role in cell growth and differentiation, giving sur-
vival advantage to cells, but there is growing evidence sug-
gesting that the activation of ERK1/2 also contributes to
cell death [14–20]. Cisplatin can activate multiple signal-
ing pathways, including c-JUN N-terminal kinase (JNK),
ERK, and p38 in cultured tubular cells but there is no in
vivo data and their specific role in mediating renal dys-
function remains unknown.
Recent several reports demonstrating that the inhibi-
tion of ERK1/2 pathway reduces the infarct volume to-
gether with down-regulation of interleukin-1b (IL-1b)
expression in focal cerebral ischemia animal model, and
also reduces cisplatin-induced caspase 3 activation with
resultant decrease in apoptosis in cultured renal tubular
cells prompted us to investigate the effect of ERK1/2 in-
hibition on cisplatin-induced renal injury in vivo [18, 20].
Because the increase of TNF-a production and caspase
458
Jo et al: ERK1/2 inhibition attenuates cisplatin-induced ARF in mice 459
activation are thought to be important in the pathogenesis
of cisplatin-induced renal injury, we examined the effect
of ERK1/2 inhibition on their tissue expression, as well as
on inflammation and apoptosis in cisplatin-induced acute
renal failure (ARF) in mice. We found that inhibiting
ERK1/2 pathway reduced TNF-a expression and caspase
activation in kidney tissue, as well as providing functional
and histologic protection in cisplatin-induced renal injury
in mice. Phosphorylated ERK1/2 were mainly localized
in distal tubules and collecting ducts. These results in-
dicate that ERK1/2 pathway is an upstream signal for
TNF-a production and caspase activation in cisplatin-
induced renal injury and targeting ERK1/2 pathway can
be a novel therapeutic strategy for the prevention of cis-
platin nephrotoxicity.
METHODS
Animals and drugs
Male balb/c mice (20 to 25 g) were purchased from
Orient (Charles River Korea, Seoul, Korea) and had free
access to water and chow before manipulation. Animal
care followed the criteria of animal care committee of
Korea University for the care and the use of laboratory
animal in research. Cisplatin (Sigma-Aldrich, St. Louis,
MO, USA) was dissolved in normal saline at a concentra-
tion of 2 mg/mL and mice were given a single intraperi-
toneal injection of 20 mg/kg cisplatin and control animals
received same volume of normal saline. One hour before
cisplatin administration, either vehicle [0.1% dimethyl
sulfoxide (DMSO) in normal saline] or U0126 (A.G. Sci-
entific, Inc., San Diego, CA, USA) (10 mg/kg, in 0.1%
DMSO) was injected intravenously via tail vein. Mice
were sacrificed at 24, 48, and 72 hours after cisplatin ad-
ministration. Blood was collected by intracardiac punc-
ture and both kidneys were processed for histology, RNA,
and protein isolation, respectively.
Biochemical analysis
Blood urea nitrogen (BUN) and creatinine levels were
measured using Hitachi 747 automatic analyzer.
Histologic examination
Paraformaldehyde (4%) fixed and paraffin-embedded
kidney tissues were stained with periodic acid-Schiff
(PAS) or naphthol AS-D chloroacetate esterase (Sigma
Aldrich). Histologic changes in outer medulla were eval-
uated semiquantitatively. Briefly, tubular damage was es-
timated in 8 to 10 high power fields (HPF) (×200) per
section by using scoring system based on the percentage
of damaged tubules per field (1, < 25%; 2, 25% to 50%;
3, 50% to 75%; and 4, > 75%). The mean score of each
animal was compared. Esterase-positive leukocyte infil-
tration was measured by counting 8 to 10 HPF (×200) per
section. For immunohistochemical detection of phospho-
ERK1/2, kidney tissue sections were treated with 1:100
rabbit antiphospho ERK1/2 polyclonal antibody (Cell
Signaling Technology, Beverly, MA, USA) and then in-
cubated with goat antirabbit HRP for 1 hour at room
temperature. The sections were developed in stable di-
aminobenzidine (DAB) and counterstained with Mayer
hematoxylin.
Detection of apoptosis
Detection of apoptotic cells in kidney was performed
on paraffin-embedded kidney tissue sections using a
ApopTag Plus (Intergen, Purchase, NY, USA), following
the manufacturer’s protocol. The number of apoptotic
cells in outer medulla was semiquantitatively measured
by counting 8 to 10 HPF (× 200) per section.
Western blot analysis
Kidney tissues were homogenized in phosphate-
buffered saline (PBS) with protease inhibitor cocktail
(Calbiochem, San Diego, CA, USA) and the pro-
tein concentration was quantitated (BCA protein assay
reagent) (Pierce, Rockford, IL, USA). Samples of pro-
tein (30 lg) were separated by 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and then transferred onto a polyvinylidene difluoride
(PVDF) membrane. Western blot analysis was per-
formed using antibody for phopho-ERK1/2, phospho-
JNK, phospho-p38 (New England Biolabs, Beverly, MA,
USA), and blots were striped and reprobed with antibody
for total ERK1/2, total JNK, and total p38 (New England
Biolabs).
Quantitation of TNF-a mRNA by real-time reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated by using TRIzol reagent (Life
Technology, Rockville, MD, USA) according to the man-
ufacturer’s protocol. After precipitation by isopropyl
alcohol, total RNA was subjected to further purifica-
tion using RNeasy minikit (Qiagen, Valencia, CA, USA).
One microgram of total RNA was reverse transcribed
in a reaction volume of 50 lL using Superscript II re-
verse transcriptase and random primers. The real-time
PCR was run in triplicate on the iCycler System (Bio-
Rad, Hercules, CA, USA) with using gene specific primer
and probe sets provided as a Pre-Developed TaqMan
Assay Reagents (PDAR) (Applied Biosystem Inc., Fos-
ter City, CA, USA), following the manufacturer’s pro-
tocol. Amplification condition was 40 cycles of 95◦C, 15
seconds, and 60◦C, 1 minute. The abundance of TNF-a
gene expression was normalized to the expression of 18S
(Taqman Ribosomal Control Reagent) (Applied
Biosystem Inc.) and was expressed as fold differences
relative to saline-treated control animals.
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Fig. 1. Effect of U0126 on phosphorylation of ERK1/2, p38, and JNK in cisplatin-induced ARF in mice. Mice were either injected with saline
(control), or 20 mg/kg cisplatin (Cis) intraperitoneally. Vehicle (V) [0.1% dimethyl sulfoxide (DMSO) in normal saline] or U0126 (U) (10 mg/kg
in 0.1% DMSO in normal saline) were injected 1 hour before cisplatin administration and sacrified at 24, 48, and 72 hours. Western blots for
phospho-ERK1/2, p38, and JNK were performed and then the blots were striped and reprobed with antibody for total ERK1/2, p38, and JNK.
Measurement of caspase activity
The activities of caspase 3, 8, and 9 in kidney tissue
were determined by fluorometric detection of free 7-
amino-4-trifluoromethylcoumarin (AFC) (caspase 3 and
8) or 7-amino-4-methylcoumarin (AMC) (caspase 9), fol-
lowing the manufacuturer’s protocol (ApoAlertTM Cas-
pase Fluorescent Assay Kits) (BD Bioscience, Palo Alto,
CA, USA) by using SynergyTM HT Multi-Detection Mi-
croplate Reader (Biotek, Woburn, MA, USA). Briefly,
kidney tissues were homogenized in 1 mL of lysis buffer,
incubated on ice for 10 minutes and centrifuged at
15,000 × g for 10 minutes at 4◦C. Supernatant contain-
ing 500 lg of protein was incubated for 1 hour at 37◦C
in the presence of reaction buffer, 1 mmol/L dithio-
threitol (DTT) and 50 lmol/L AMC or AFC substrate
conjugates. The fluorescence was read at 400/505 (excita-
tion/emission) nm for caspase 3 and 8 and 380/460 nm for
caspase 9 and the samples were run in triplicates. The ac-
tivity of caspases was expressed as percent increase com-
pared to saline-treated control group and samples which
has caspase inhibitors served as negative controls.
Statistical analysis
All data presented as mean ± SE and were analyzed
by Student t test. P value less than 0.05 was considered
statistically significant.
RESULTS
ERK1/2 phosphorylation increased in kidney
tissue following cisplatin administration
First, we examined the changes in phosphorylation of
ERK1/2 in cisplatin-induced ARF. ERK1/2 phosphory-
lation increased from 24 hours after cisplatin administra-
tion and persisted until 72 hours (Fig. 1). To make sure
the specificity of U0126 in inhibiting ERK1/2, we also
did Western blot analysis of phospho-JNK and p38 and
found that there were no inhibitory effects of U0126 on
phosphorylation of JNK, p38 despite increased phospho-
rylation by cisplatin. In immunohistochemistry, phospho-
ylated ERK was detected in occasional collecting duct
cells in control kidneys, but not in glomeruli or proxi-
mal tubules. Following cisplatin administration, phospho-
ERK expression markedly increased mainly in distal
tubules and collecting ducts (Fig. 2). The staining was
mostly in cytosol, but a few cells showed strong positive
nuclear staining.
Effect of U0126 on renal damage following
cisplatin administration
To clarify the role of ERK1/2 pathway in cisplatin-
induced ARF, we injected a specific MEK1/2 inhibitor,
U0126, 1 hour before cisplatin administration. Renal
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Fig. 2. Immunohistochemical localization of phospho-ERK1/2 in kidneys from control, vehicle + cisplatin, and U0126 + cisplatin-treated mice.
Mice were either injected with saline (control), or 20 mg/kg cisplatin (Cis) intraperitoneally. Vehicle [0.1% dimethyl sulfoxide (DMSO) in normal
saline] or U0126 (10 mg/kg in 0.1% DMSO in normal saline) were administered 1 hour before cisplatin administration. Immunohistochemistry for
phospho-ERK1/2 was done at 72 hours. (A) Control. (B, D, and E) Vehicle + cisplatin. (C) U0126 + cisplatin [magnification (A to C) ×40, (D)
×100, (E) ×200].
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Fig. 3. Effect of U0126 on renal function in
cisplatin-induced ARF in mice. Mice were
either injected with saline (control), or 20
mg/kg cisplatin (Cis) intraperitoneally. Ve-
hicle [0.1% dimethyl sulfoxide (DMSO) in
normal saline] or U0126 (10 mg/kg in 0.1%
DMSO in normal saline) were intravenously
injected 1 hour before cisplatin administration
and sacrificed at 24, 48, and 72 hours. Ani-
mals injected intravenously with U0126 (U)
alone served as U0126 control (C). Data were
presented as mean ± SE (N = 5 animals per
group). #P < 0.05 compared to control; ∗P <
0.05 compared to vehicle + cisplatin.
function was measured at 24, 48, and 72 hours and his-
tologic changes were compared at 72 hours. U0126 itself
had no effect on renal function (Fig. 1). U0126 pretreat-
ment reduced the phosphorylation of ERK1/2 at 24, 48,
and 72 hours (Fig. 1), and these changes were accompa-
nied by marked functional protection (Fig. 3). The im-
provement in renal function was also reflected in less
severe histologic damage at 72 hours (Fig. 4). Cisplatin
caused loss of brush border, necrosis of tubular cells,
cast formation, and these changes were significantly at-
tenuated in U0126 pretreated animals. Semiquantitative
assessment of histologic damage also showed a signifi-
cant beneficial effect of U0126 in cisplatin-induced ARF
(Fig. 4).
Effect of U0126 on TNF-a mRNA expression
and leukocytes infiltration
Because there have been several reports suggesting
that TNF-a play an important pathogenetic role in cis-
platin nephrotoxicity, we examined the effect of U0126
on TNF-a gene expression by real-time quantitative
RT-PCR. Like other studies, TNF-a mRNA expression
markedly increased following cisplatin administration.
The up-regulation was evident from 24 hours and per-
sisted until 72 hours and U0126 almost completely abol-
ished TNF-a abundance at each time point (Fig. 5).
Since TNF-a has been known to incite an inflammatory
reaction, we performed naphthol-AS-D chloroacetate
staining and counted the number of esterase positive
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Fig. 4. Effect of U0126 on renal histology
in cisplatin-induced ARF in mice. Mice were
injected intravenously with either vehicle or
U0126 (10 mg/kg) 1 hour before cisplatin (Cis)
administration intraperitoneally. Renal his-
tology was examined at 72 hours. Semiquanti-
tative assessment of renal damage was scored
as described in the Methods section. (A) Ve-
hicle + cisplatin, (B) U0126 + cisplatin, (C)
Semiquantitative histologic injury score. (A
and B) Periodic acid-Schiff (PAS) × 200 (N =
4 animals per group). ∗P < 0.05 compared to
vehicle + cisplatin.
leukocytes in kidney tissue. Esterase positive leukocytes
infiltration increased markedly at 48 and 72 hours in
outer medulla and U0126 pretreatment also significantly
reduced the leukocytes infiltration at each time point
(Fig. 6).
Effect of U0126 on caspase activation and apoptosis
Caspases are cysteine proteases responsible for apop-
totic cell death and can be activated by many different
stimuli. Caspases can be divided into an initiator and ex-
ecutioner caspases. Generally, the activation of initiator
caspases, like caspase 8 or 9 lead to the activation of ex-
ecutioner caspases like caspase 3 via different cell death
pathway. Although renal tubular cell apoptosis through
caspase activation by cisplatin has been demonstrated in
several in vitro studies, there has been no in vivo data
showing the activation of caspase following cisplatin ad-
ministration. Therefore, we examined various caspase ac-
tivations following cisplatin administration and also the
effect of U0126 pretreatment on their activities. The ac-
tivation of caspase 3, an executioner caspase increased
markedly at 24 hours after cisplatin, peaked at 48 hours
and started to decrease at 72 hours. U0126 pretreatment
significantly decreased the activation at each time point
(Fig. 7). The activities of caspase 8 and 9 also increased
slightly, but much lesser degree than that of caspase 3
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Fig. 5. Effect of U0126 on tumor necrosis factor-a (TNF-a) mRNA ex-
pression in cisplatin-induced acute renal failure (ARF) in mice. TNF-a
mRNA expression was measured at 24, 48, and 72 hours after injec-
tion of vehicle + cisplatin or U0126 + cisplatin by real-time reverse
transcription-polymerase chain reaction (RT-PCR). In each experi-
ment, the level was normalized to the expression of 18 S and were
expressed as fold differences relative to saline-treated control animals.
Data are presented as mean ± SE (N = 4 animals per group). ∗P < 0.05
compared to vehicle + cisplatin.
and did not precede the activation of caspase 3, indicating
that the activation of caspase 3 is independent of caspase
8 or 9 in this model (Fig. 7). Morphologically, terminal
deoxynucleotidyl transferase-mediated uridine triphos-
phate (dUTP) nick-end labeling (TUNEL)-positive cells
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Fig. 6. Effect of U0126 on leukocycytes in-
filatration in cisplatin-induced ARF in mice.
Eight to ten × 200 fields were counted
and mean numbers of esterase-positivie
leukoyctes were compared. (A) Panels A and
C are vehicle + cisplatin. Panels B and D
are U0126 + cisplatin, Panels A and B are
at 48 hours and panels C and D at 72 hours
(naphthol AS-D chloroacetate esterase stain-
ing ×400). (B) Mean numbers of leukocytes
(N = 4 animals per group). ∗P < 0.05 com-
pared to vehicle + cisplatin.
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U0126 (10 mg/kg) 1 hour before cisplatin ad-
ministration intraperitoneally. Detection of
apoptosis was done at 48 hours. (A) Vehi-
cle + cisplatin, (B) U0126 + cisplatin, (C)
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Fig. 7. Effect of U0126 on the activation of caspases in cisplatin-
induced acute renal failure (ARF) in mice. Tissue caspase activities
were measured at 24, 48, and 72 hours and were expressed as percent
increase compared to saline-treated control group. (A) Caspase 3 ac-
tivity. (B) Caspase 8 activity. (C) Caspase 9 activity (N = 4 animals per
group). #P < 0.05 compared to control; ∗P < 0.05 compared to vehicle
+ cisplatin (Cis).
increased in ciplatin treated animals and U0126 pretreat-
ment also significantly decreased apoptosis (Fig. 8).
DISCUSSION
In the present study, we demonstrated that (1) systemic
administration of a selective MEK inhibitor, U0126, sig-
nificantly attenuated cisplatin-induced renal injury in
mice; and (2) inhibiting ERK1/2 phosphorylation dra-
matically reduced both inflammatory, apoptotic path-
ways of renal injury in cisplatin-induced ARF in mice.
Members of MAPK family proteins play important
roles in regulating diverse cellular responses to a vari-
ety of extracellular stimuli. One of the most extensively
characterized MAPK families are ERK1/2 and has been
known to be associated with cell growth and differen-
tiation, but recent several reports suggest that ERK1/2
pathway can also be related to inflammation, apopto-
sis, and cell injury [14, 15, 17, 18, 21, 22]. In particular,
Nowak [20] demonstrated that inhibiting ERK1/2 phos-
phorylation reduced cisplatin-induced caspase 3 activa-
tion and apoptosis in cultured renal proximal tubular
cells, suggesting ERK1/2 pathway can be a therapeutic
target in cisplatin-induced renal dysfunction. However,
because most of our understanding of how MAPK signal-
ing promotes cell injury is based on cell culture studies,
we have little knowledge of how ERK1/2 pathway reg-
ulates cellular responses to extracellular stimuli in vivo.
We therefore first examined the ERK1/2 phosphorylation
following cisplatin administration in mice. ERK1/2 phos-
phorylation increased from 24 hours and continued to in-
crease until 72 hours after cisplatin administration. U0126
pretreatment 1 hour before cisplatin reduced the phos-
phorylation of ERK1/2 and this inhibition was accompa-
nied by marked functionional and histologic protection
at 72 hours. This novel finding is in contrast with previous
report by di Mari, Davis, and Safirstein [21] suggesting
that ERK is critical in renal tubular cell survival during
oxidative injury. The fact that ERK1/2 activation can pro-
vide cell death or survival signal suggests that ERK1/2 can
activate different intracellular pathways that regulate cell
fate in response to different kinds of cell stresses.
The exclusive localization of phospho-ERK in distal
nephron is somewhat unexpected, because the primary
target of cisplatin is known to be proximal straight tubule
and most of in vitro experiments have used proximal
tubular cells for the study of cisplatin nephrotoxicity. But
distal nephron injury-like mitochondrial swelling, apop-
tosis, and frank necrosis also have been described and
magnesium wasting commonly seen in human cisplatin
nephrotoxicity also reflects distal nephron injury. Consti-
tutive expression of phospho-ERK1/2 in distal nephron
was also observed by Fujita et al [23] in diabetic rats.
Whether ERK1/2 activation in distal nephron mediates
distal nephron injury only or also contributes to proximal
tubule injury in this model is not clear but certain genetic
responses of distal nephrons to injuries may be maladap-
tive enough to induce not only distal nephron injury, but
also adjacent proximal tubule injury by aurocrine and
paracrine fashion.
Since the molecular mechanisms responsible for the
beneficial effect of ERK1/2 inhibition have to be
elucidated, we examined the effect of ERK1/2 inhibi-
tion on several key components involved in cisplatin-
induced renal injury. We first examined TNF-a, a
potent proinflammatory cytokine mRNA expression.
Like in other studies, TNF-a mRNA expression markedly
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increased at 24 hours, and persisted until 72 hours
after cisplatin and U0126 pretreatment significantly
reduced TNF-a abundance in kidney tissue. This indi-
cates that ERK1/2 phosphorylation is an upstream signal
in cisplatin-induced TNF-a mRNA expression. Recent
several reports demonstrating the beneficial effect of
ERK1/2 inhibition on various inflammatory parameters
and on the production of inflammatory cytokine, like IL-
1b in cerebral ischemia or acute pancreatitis model also
support our finding that ERK pathway functions as an
upstream signal mediating TNF-a production, but addi-
tional studies that can provide evidences that ERK path-
way can lead to up-regulation of several transcription
factors that can mediate TNF-a expression should also
be performed [18, 22].
The role of TNF-a in cisplatin induced renal injury has
been extensively studied by using inhibitors of TNF-a
or blocking antibody, producing less severe renal dam-
age with reduced TNF-a level [6]. This finding is further
supported by additional studies by Deng et al [5] that
a-melanocyte stimulating hormone (a-MSH) or IL-10,
which suppress the production of TNF-a also ameliorated
cisplatin-induced renal injury. Several different mecha-
nisms seem to be involved in TNF-a–mediated renal in-
jury, like apoptosis, production of reactive oxygen species,
or provocation of inflammatory response [5, 24–28]. Of
those mechanisms, inflammation seems to be important
because administration of a potent anti-inflammatory cy-
tokine, IL-10, or blocking TNF-a decreased the num-
ber of infiltrating leukocytes with functional and histo-
logic protection [6]. In our study, esterase-positive leuko-
cytes infiltration also significantly decreased in U0126
pretreated animals, suggesting that ERK1/2 phosphory-
lation mediates the inflammatory pathway in cisplatin-
induced renal injury. Although whether increased TNF-a
mRNA expression through ERK pathway directly medi-
ates inflammation is not clear in this study, a recent study
by Ramesh and Reeves [28], demonstrating TNF-a de-
pendence of leukocyte infiltration, supports that TNF-a
dependent inflammation mediated through ERK1/2 ac-
tivation plays an important role in the pathogenesis of
cisplatin-induced renal injury.
Apoptosis is now recognized as an important mode of
cell death in normal or pathologic status and character-
ized by cell shrinkage, nuclear chromatin condensation,
and activation of a family of cyteine protease called cas-
pase. The activation of caspase is thought to be a key step
in the generation of apoptosis and several in vitro studies
demonstrated that cisplatin activated multiple caspases,
including caspase 8, 9, and 3, in renal tubular cells, in-
dicating that caspase activation and subsequent tubular
cell apoptosis is also important in the pathogenesis of
cisplatin-induced renal dysfunction [13, 29, 30]. Recently,
Nowak [20] showed that the activation of caspase 3 and
apoptosis by cisplatin were decreased by inhibition of
ERK1/2, suggesting ERK1/2 pathway is an upstream sig-
nal for caspase 3 activation and subsequent apoptosis in
renal tubular cell. Because caspase 3 is one of the ex-
ecutioner caspases directly responsible for the cleavage
of diverse physiologic substrates in apoptosis, we mea-
sured the activity of caspase 3 in kidney tissue. Like other
in vitro studies, caspase 3 activity increased markedly at
24 hours, increased further to over 50-fold, peaking at
48 hours and U0126 pretreatment significantly decreased
the activation of caspase 3 at each time point. This is con-
sistent with the in vitro finding by Nowak et al [20] and to
our knowledge, it is the first time to measure kidney tissue
caspase activity and to show that ERK1/2 is an upstream
signal for caspase 3 activation in vivo. Because caspase
8, an initiator caspase from membrane death receptor-
dependent pathway, or caspase 9 from mitochondria-
dependent pathway can also result in the activation of
caspase 3, we also measured caspase 8 and 9 activities.
The activities of caspase 8 or 9 increased slightly, but nei-
ther of them showed exact temporal relationship with
that of caspase 3, indicating that the huge increase of cas-
pase 3 activity by cisplatin is independent of caspase 8 or
9 activation. This result is consistent with the finding by
Kaushal et al [13] demonstrating that the activation of
caspase 3 in porcine proximal tubular cells (LLC-PK1)
far preceded those of caspase 8 or 9, suggesting an inde-
pendent activation of caspase 3 by cisplatin. The role of
caspase 8 or 9 in cisplatin-induced tubular cell apoptosis
has been controversial. Tsuruya et al [31] reported that
Fas and TNFR1-mediated apoptosis is directly involved
in renal tubular cell death in murine model of cisplatin-
induced ARF, suggesting the important role of caspase
8, but they did not determine the tissue caspase activity.
Park, De Leon, and Devarajan [32] demonstrated the role
of cytochrome c and caspase 9 dependent apoptotic path-
way, but it was not an in vivo study. In our study, however,
we observed the significant activation of caspase 3, but
not caspase 8 or 9, suggesting the activation of caspase
3 is contributed by the other pathways. Because recent
several studies have demonstrated that cisplatin-induced
ERK activation is an upstream regulator of p53 which
can subsequently induce cell cycle arrest and apoptosis,
p53 may partially be responsible for huge increase in cas-
pase 3 activity independent of caspase 8 or 9 in this study
[33, 34]. The p53-dependent activation of caspase 3 and
apoptosis in renal tubular cells have been also demon-
strated by Cummings and Schnellmann [10] who showed
that adding p53 inhibitor significantly reduced caspase
3 activation and apoptosis by cisplatin. The number of
TUNEL-positive apoptotic cells significantly increased
in cisplatin-treated animals and U0126 pretreatment de-
creased the morphologic evidence of apoptosis. Although
many other factors, like proinflammatory cytokine, reac-
tive oxygen species can induce apoptosis, the activation of
caspase 3 is thought to be a key step in apoptosis in this
model because direct causal relationship between cas-
pase 3 activation and apoptosis has been demonstrated
466 Jo et al: ERK1/2 inhibition attenuates cisplatin-induced ARF in mice
from many other in vitro and in vivo studies using caspase
inhibitor [32, 35–37].
CONCLUSION
The present study demonstrates that the inhibition of
ERK1/2 pathway provided marked functional, histologic
protection in cisplatin-induced ARF in mice. The mech-
anism of this beneficial effect is thought to be mediated
by inhibition of TNF-a–mediated inflammation and cas-
pase 3–mediated apoptosis of tubular cells. Elucidating
the signaling mechanism can lead to a better understand-
ing of pathogenetic mechanism of renal dysfunction and
targeting ERK1/2 can be a novel therapeutic strategy to
inhibit or reduce cisplatin nephrotoxicity.
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